Immunotherapy for Advanced Skin Cancer: Mechanism, Checkpoint Inhibitors, and Clinical Outcomes

Clinical Overview

Immunotherapy, particularly checkpoint inhibitor monoclonal antibodies targeting PD-1 (programmed death-1) and CTLA-4 (cytotoxic T lymphocyte antigen-4) pathways, has revolutionized treatment of advanced melanoma and other skin cancers. These drugs block inhibitory signals that prevent T cells from attacking tumor cells, thereby unleashing anti-tumor immune response. Pembrolizumab (anti-PD-1) and nivolumab (anti-PD-1) are FDA-approved for metastatic melanoma with response rates of 40-50% as single agents and 60% with combination therapy. Ipilimumab (anti-CTLA-4) has response rates of 20-30% as single agent. Combination nivolumab plus ipilimumab achieves response rates exceeding 60% with median overall survival >60 months in responding patients (CheckMate 067). The success of checkpoint inhibitor immunotherapy in melanoma is driven by high tumor mutational burden and abundance of tumor-infiltrating lymphocytes, making melanoma highly immunogenic. However, immune-related adverse events (irAEs) occur in 50-90% of patients receiving checkpoint inhibitors, requiring vigilant monitoring and management.

Epidemiology & Risk Factors

Melanoma is among the most immunogenic human cancers, with high response rates to checkpoint inhibitors compared to other malignancies. Approximately 40-50% of metastatic melanoma patients respond to PD-1 inhibitor monotherapy, with response rates varying by tumor characteristics: higher response rates in tumors with PD-L1 expression (though PD-L1 status is not predictive enough to withhold immunotherapy from PD-L1 negative patients), higher response in high tumor mutational burden, and higher response in tumors lacking BRAF mutations (wild-type BRAF tumors have higher response than BRAF-mutant tumors to immunotherapy). BRAF-mutant metastatic melanoma may preferentially respond to targeted therapy (BRAF/MEK inhibitors) rather than immunotherapy, though combined approaches are under investigation.

Pathophysiology

Checkpoint inhibitor immunotherapy works by blocking inhibitory pathways that normally suppress T-cell response. PD-1 is an inhibitory receptor on T cells; when PD-1 ligands (PD-L1, PD-L2) expressed by tumor cells or immune cells bind PD-1, they send a "stop signal" to T cells, preventing anti-tumor immunity. Anti-PD-1 monoclonal antibodies (pembrolizumab, nivolumab) block this interaction, allowing T cells to attack tumor cells. CTLA-4 is another inhibitory checkpoint on T cells; anti-CTLA-4 monoclonal antibody (ipilimumab) blocks CTLA-4, enhancing T-cell activation early in immune response. Combination anti-PD-1 plus anti-CTLA-4 targets both early (CTLA-4) and late (PD-1) stages of T-cell activation, resulting in superior response rates but increased immune-related adverse events. The effectiveness of checkpoint inhibitors depends on baseline anti-tumor immune response: tumors with high baseline T-cell infiltration and high tumor mutational burden respond better than tumors with low T-cell infiltration or low mutational burden.

Clinical Presentation & Classification

Metastatic melanoma (Stage IV) with visceral, nodal, or distant skin/soft tissue metastases is considered for immunotherapy. Patients should have adequate organ function (hepatic, renal function), no active autoimmune disease (relative contraindication), and performance status 0-2 (ECOG scale). Baseline imaging (CT chest/abdomen/pelvis, brain MRI if indicated) documents metastatic sites for response assessment. Baseline laboratory studies (CBC, comprehensive metabolic panel, LDH) are obtained. Baseline assessment of immune-related adverse events (autoimmune history, autoimmune serologies, thyroid function, etc.) helps predict risk of future complications.

Diagnosis & Staging

Metastatic melanoma diagnosis requires histopathologic confirmation of melanoma at metastatic site (or confirmation that metastasis is same melanoma as primary based on clinical/radiologic features). Response to immunotherapy is assessed by: (1) Radiographic response: RECIST v1.1 criteria measuring tumor size on CT/MRI (complete response, partial response, stable disease, progressive disease); (2) Clinical examination: assessment of palpable metastases; and (3) Laboratory markers: LDH level (elevated LDH indicates higher tumor burden and worse prognosis; normalization of elevated LDH with treatment indicates favorable response). Immune-related adverse events are assessed and graded (Grade 1-4 per CTCAE v5.0 criteria). Response assessment imaging is typically performed every 8-12 weeks during immunotherapy.

Treatment Algorithm

First-line systemic therapy for metastatic melanoma without BRAF mutation (wild-type): pembrolizumab 200mg IV every 3 weeks or nivolumab 3mg/kg IV every 2 weeks, both achieving ~40-50% response rates with median PFS of 11-12 months. Combination nivolumab 1mg/kg plus ipilimumab 3mg/kg every 3 weeks for 4 doses (induction), then nivolumab maintenance (240mg IV every 2 weeks), achieves ~60% response rate but with increased irAEs (90% any grade, 40-60% Grade 3-4 irAEs). For BRAF V600E-mutant metastatic melanoma: BRAF/MEK inhibitor therapy (dabrafenib 100mg twice daily plus trametinib 2mg daily) achieves 64-70% response rates, or checkpoint inhibitor immunotherapy, or combined approaches. For PD-L1 expressing tumors and immunotherapy-resistant or relapsed patients: additional options include chemotherapy (dacarbazine, temozolomide) with response rates of 10-15%, or combination approaches. Ongoing clinical trials are evaluating: combination immunotherapy with targeted therapy, immunotherapy plus radiation therapy, and immunotherapy plus antiangiogenic agents.

Prognosis & Survival

Metastatic melanoma without immunotherapy had median overall survival of 6-12 months. With single-agent immunotherapy (pembrolizumab or nivolumab), median OS is 18-24 months. With combination immunotherapy (nivolumab plus ipilimumab), median OS is >60 months in responding patients, though median follows delayed since tail of survival curve extends well beyond 5 years. Importantly, ~20-30% of patients achieve durable complete responses with long-term survival (5+ years) with immunotherapy. Prognostic factors include: baseline LDH (elevated LDH indicates worse prognosis), BRAF mutation status (wild-type better response to immunotherapy), number of metastatic sites, and response to immunotherapy (complete/partial responders have substantially better outcomes than stable disease/progressive disease). Checkpoint inhibitor irAEs can substantially impact quality of life but rarely are fatal with appropriate management; death from irAEs is <1% with experienced management.

When to See a Dermatologist

Patients with metastatic melanoma should be referred to medical oncology for systemic therapy evaluation. Dermatologists remain involved in surveillance for cutaneous metastases, recurrence at primary site, and new primary melanomas (which occur in 3-5% of melanoma patients). Dermatologists also help monitor for immunotherapy-related skin toxicities (dermatitis, lichenoid reactions, vitiligo).

Frequently Asked Questions

What does checkpoint inhibitor immunotherapy do to fight my melanoma?

Checkpoint inhibitors block inhibitory signals that prevent your T cells (immune cells) from attacking melanoma cells. Normally, melanoma cells evade immune attack by expressing molecules that tell T cells to "stop." Checkpoint inhibitors remove this "stop signal," allowing your own T cells to recognize and attack melanoma cells. This unleashes your immune system's natural anti-tumor response.

If immunotherapy works, could I stop it after my tumors shrink?

Treatment duration depends on response and tolerability. Pembrolizumab is typically given for up to 2 years or until disease progression or unacceptable toxicity. Nivolumab can be continued indefinitely. Early discontinuation after response is not recommended, as this may allow recurrence. Your oncologist will discuss optimal duration based on your individual response and side effects.

What are immune-related adverse events, and how serious are they?

Immune-related adverse events (irAEs) are side effects resulting from immune system activation against normal body tissues. Common irAEs include: skin reactions (rash, vitiligo), gastrointestinal problems (diarrhea, colitis), thyroid dysfunction, pneumonitis (lung inflammation), and hepatitis. Most irAEs are manageable with supportive care or short-term corticosteroids; severe irAEs (Grade 3-4) occur in 40-60% of patients receiving combination immunotherapy but are usually manageable with appropriate treatment. Fatal irAEs are rare (<1%) with experienced management.

I have an autoimmune disease. Can I receive immunotherapy?

Active autoimmune disease is considered relative contraindication to checkpoint inhibitor immunotherapy due to risk of autoimmune exacerbation. However, patients with controlled autoimmune disease may be considered for immunotherapy with careful monitoring. Discuss your autoimmune history with your oncologist, who will weigh risks/benefits and may consider single-agent anti-PD-1 (lower irAE rate) versus combination therapy.

References

  1. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23-34.
  2. Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823-1833.
  3. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo in resected Stage III IIM melanoma (EORTC 18071). Lancet Oncol. 2015;16(5):522-530.
  4. Weber JS, Carlino MS, Khattak A, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus placebo plus pembrolizumab in resected melanoma (KEYNOTE-942). Lancet. 2022;400(10368):1682-1696.
  5. Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813-1823.
  6. Schadendorf D, van Akkooi AC, Berglund A, et al. Melanoma. Nat Rev Dis Primers. 2018;4:18076.
  7. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80(1):208-250.
  8. Coit DG, Thompson JA, Algazi A, et al. Melanoma, version 2.2019: NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(4):367-402.
  9. Khatri R, Berman B, Blitzblau R. Checkpoint inhibitors for cutaneous melanoma: current status and future directions. J Am Acad Dermatol. 2017;76(3):355-366.
  10. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000;18(1):158-166.

Last updated: March 2026. This article reflects current evidence-based clinical practice and is intended for healthcare professionals and informed patients. Always consult with a board-certified dermatologist for personalized medical advice.